Accessing Library
Connecting to Pep Nation Lab's research database...
Connecting to Pep Nation Lab's research database...
Select Up To Four Compounds To Review Their Evidence, Targets, And Handling Side By Side.
For Laboratory Research Only



| Attribute | ||
|---|---|---|
Research Summary | Semax is like a heavy cup of coffee for your brain but without the jitters. Originally developed in Russia, it sharpens your focus, improves your memory, and protects your brain from stress. | Cerebrolysin is like plant food for your brain. It helps broken brain cells heal after an injury (like a stroke or a hard hit) and helps healthy brain cells grow new connections so you can think clearer. |
Studied For | Ischemic stroke recoveryCognition / memory enhancementOptic nerve disordersCNS disorders researchADHD researchBDNF upregulationNeuroprotectionAnxiety reductionDepression modelsTransient ischemic attack (TIA) modelsSerotonin upregulationDopamine enhancementFocus and attention researchImmune modulationMelanocortin system cognitive effectsNeurogenesis researchPost-stroke cognitive improvementbrain fogcognitive enhancementADHDstroke recoveryneuroprotectionmemory improvementBDNF increasefocus | Acute ischemic stroke recoveryTraumatic brain injury (TBI)Vascular dementiaAlzheimer's-type dementiaCognitive impairment recoveryNeuroprotectionNeuroregenerationBDNF and NGF pathway stimulationPost-stroke rehabilitationParkinson's disease researchADHD researchMemory enhancementAnti-apoptotic neuronal protectionNeuroplasticity promotionSpine injury modelsCerebral ischemia protectionAge-related cognitive declineTBI recoveryAlzheimer's researchdementianeurogenesisstroke recoverycognitive declineneurological repair |
Research Areas | CognitiveImmuneLongevity | CognitiveHealing & RecoveryLongevity |
Best Stacked With | selankpinealoncerebrolysinnad-plusbac-water | semaxselankpinealonnad-plus |
Overview | ||
Category | Immunity & Wellness | Immunity & Wellness |
Compound Class | Synthetic heptapeptide analog of ACTH 4-7 with Pro-Gly-Pro extension; neuroprotective and nootropic | Porcine brain-derived standardized peptide hydrolysate (<10 kDa peptides); neurotrophic factor mimetic |
Molecular Target | Melanocortin receptors (MC2R/MC4R); BDNF/NGF upregulation; serotonin/dopamine axis; enkephalinase inhibition | BDNF/TrkB pathway; NGF/TrkA pathway; anti-apoptotic (Bcl-2 upregulation); antioxidant; glutamate excitotoxicity protection |
Aliases / AKA | Semax peptideACTH 4-7 PGPMet-Glu-His-Phe-Pro-Gly-ProSemax nasal sprayACTH analog nootropicHeptapeptide nootropic | FPF-1070Cerebrolysin injectionPorcine brain peptide hydrolysateBrain peptide mixtureNeurotrophic peptide mixtureEVER Neuro Pharma cerebrolysin |
Parent Compound | ACTH(4-10) fragment | Porcine brain proteins |
Molecular Weight | 813.9 Da | mixture |
Amino Acid Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | standardized peptide mixture (<10 kDa) |
CAS Number | 80714-61-0 | not applicable |
Year Discovered | Not Listed | Not Listed |
Pro-Angiogenic | No | No |
GLP-1 Class | No | No |
Purity | Not Listed | Not Listed |
Identity | ||
Evidence Tier | ||
Risk Level | ||
PubMed Citations | 314 Good | 2,579 Extensive |
Clinical Trials | Not Listed | 2323 Active |
Regulatory Status | Registered in Russia; not FDA or EMA approved. | Approved in many EU/Asia/CIS countries; not FDA-approved. |
Evidence & Regulatory | ||
Half-Life | ~5 minutes | ~20-30 minutes |
Typical Frequency | Not Listed | Not Listed |
Administration Route | Injection Only | Injection Only |
Mechanism / PK | Not Listed | Not Listed |
Reported Findings | Russian use and studies report benefit in stroke and cognition. Animal data show neuroprotection and improved learning. Predominantly Russian-literature and preliminary. | Approved in many countries for stroke, TBI, and dementia. Trial evidence is mixed: some subgroup benefits, but a large stroke trial was negative and a 2020 Cochrane review found insufficient evidence in acute ischemic stroke. |
Side Effects Noted | Reported well tolerated; intranasal local irritation; limited independent adverse-event data. | Generally tolerated; injection-site reactions, dizziness, agitation, sweating; theoretical porcine allergy. |
Warnings | Thin, geographically concentrated evidence; registered in Russia but not FDA or EMA approved. Research use only elsewhere. | Contraindicated in hypersensitivity, status epilepticus, and severe renal impairment per foreign labeling. Not FDA-approved. |
Pharmacology | ||
Form | lyophilized | sterile aqueous solution (not lyophilized) |
Diluent | bacteriostatic water | used as-is |
Storage Temp | frozen, dark | protect from light |
Light Sensitive | Yes | Yes |
Freeze / Thaw | avoid | n/a |
Handling Notes | Often studied as an intranasal formulation. | Do not co-infuse with amino-acid solutions; batch variability. |
Reconstituted Shelf Life | 28 Days Refrigerated | Not Listed |
Handling & Storage | ||
Pep Nation Lab's comparison tool puts research-grade peptides and compounds head to head - mechanism of action, molecular target, evidence tier, molecular weight, sequence, half-life, and documented research focus - so qualified researchers can evaluate the differences that matter. Every data point is drawn from a referenced monograph. For in vitro laboratory research use only.
The two most-studied research peptides for tissue repair and recovery.
Single GLP-1 versus dual GLP-1/GIP incretin agonists in metabolic research.
Dual versus triple incretin receptor agonists in weight-research models.
A GLP-1 agonist versus a triple-agonist incretin in metabolic research.
A GHRH analog versus a selective ghrelin-receptor secretagogue.
A ghrelin-receptor secretagogue versus a GHRH analog for growth-hormone research.
Two GHRH analogs studied on the growth-hormone axis.
The two first-generation growth-hormone releasing peptides.
An amylin analog versus a GLP-1 agonist in metabolic research.
A mitochondrial-derived peptide versus an HGH fragment in metabolic research.
Melanocortin versus kisspeptin pathways in reproductive research.
A telomerase-pathway peptide versus NAD+ metabolism in longevity research.
A potent versus a highly selective ghrelin-receptor secretagogue.
Two GHRH analogs with contrasting half-life profiles.
A direct IGF-1 analog versus a growth-hormone secretagogue.
The DAC versus non-DAC forms of the CJC-1295 GHRH analog.
Two Russian-developed nootropic and anxiolytic research peptides.
Two mitochondrial-targeted peptides in cellular-energy research.
Two immune-modulating research peptides with distinct mechanisms.
Two HGH-fragment analogs studied for fat-metabolism research.
Next-generation multi-receptor incretin agonists in metabolic research.
Two leading tissue-repair peptides with distinct healing mechanisms.
A systemic repair peptide versus a copper peptide for tissue and skin research.
A GHRH analog versus a selective ghrelin-receptor secretagogue on the GH axis.
A dual incretin agonist versus an amylin analog in metabolic research.
A triple incretin agonist versus an amylin analog in weight research.
Two metabolic research compounds targeting mitochondrial and NNMT pathways.
NAD+ metabolism versus a mitochondrial-derived peptide in longevity research.
Two copper research peptides studied for skin and hair.
A long-acting versus a short-acting GHRH analog.
A selective versus a first-generation ghrelin-receptor secretagogue.
A GLP-1 agonist versus a GLP-1/amylin combination in metabolic research.
Two peptides studied for gut and mucosal repair.
Melanocortin versus oxytocin pathways in intimacy and libido research.
Two thymic immune-modulating research peptides.
An anxiolytic nootropic versus a sleep-associated research peptide.
Direct IGF-1 signaling versus myostatin inhibition in muscle research.
A mitochondrial-targeted peptide versus NAD+ in cellular-energy research.
Single BPC-157 versus the combined BPC-157 and TB-500 blend in recovery research.
Ipamorelin alone versus the CJC-1295 and ipamorelin blend on the growth-hormone axis.
A synthetic ACTH-fragment nootropic versus a neurotrophic peptide preparation in cognitive research.
Two sleep-research compounds with distinct mechanisms.
A copper tripeptide versus an acetyl hexapeptide in cosmetic and skin research.
A senolytic peptide versus a telomerase-pathway peptide in longevity research.
Two metabolic research compounds targeting the AMPK and NNMT pathways.
A GHRH analog versus an HGH fragment in fat-metabolism research.
Two AMPK-associated mitochondrial and metabolic research compounds.
Two peptides studied for tissue protection and repair.
Two peptides studied for immune and inflammatory modulation.
Two peptide bioregulators studied in longevity and neuro research.
A glucagon/GLP-1 dual agonist versus a GIP/GLP-1 dual agonist in metabolic research.
Browse the full research catalog or the A To Z index to compare any compound.
Any research-grade compound in the library can be placed side by side - up to four at a time. The tool compares mechanism of action, molecular target, evidence tier, molecular weight, amino acid sequence, reported half-life, and what each compound has been studied for, all drawn from referenced monographs.
The evidence tier reflects how extensively a compound has been studied in the referenced literature, from early preclinical signals through to compounds with human clinical data. It is a research-quality signal only, never a safety or efficacy endorsement.
Each comparison page is generated from the same referenced compound database - a genuine side-by-side of mechanism, identity, pharmacokinetics, and evidence, plus data-derived key differences. They are curated, not auto-generated thin pages.
No. Every comparison is for in vitro laboratory research use only. Nothing here is medical advice, a treatment recommendation, or dosing guidance, and no product is for human or animal consumption.